Jami Taylor is Global Policy Leader for the Janssen Diagnostics organization within Johnson & Johnson (J&J). Situated within J&J’s pharmaceutical sector, Janssen Diagnostics is the focal point for the fulfillment of J&J’s vision for personalized medicine, vision that extends across a broad range of therapeutic areas and pipeline products.

In her current role, Jami serves as the key two-way linkage between Janssen Diagnostics and J&J Government Affairs & Policy, supporting an enterprise-wide, global effort to help shape the future of personalized medicine policy for the benefit of patients.

As part of this global effort, Jami leads J&J’s outreach to external stakeholders in personalized medicine policy. She is currently co-chair of the Personalized Medicine Diagnostics Working Group at the Biotechnology Industry Organization, vice-chair of the Education Committee of the European Personalised Medicine Association (EPEMED), and the J&J designate to the EPEMED Board of Directors. Jami is also an active member of the Personalized Medicine Coalition’s Public Policy Committee and of the European Biopharmaceutical Enterprises’ Personalised Medicine Task Force.

Jami joined J&J in January 2011 after more than 10 years in public affairs consulting, where she specialized in alliance development, policy communications, and issue-campaign design and execution. Her experience includes work with the White House Office of Public Liaison, members of Congress, and the Departments of Treasury, Commerce, and Health & Human Services to advance legislative priorities on a nationwide scale.

Jami is a contributing editor of Global Pharmacovigilance Laws & Regulations: The Essential Reference, a book published by the Food & Drug Law Institute (FDLI) in Spring 2009. She also served as a vice-chair of FDLI’s inaugural conference on U.S.-China Food and Drug Law, held in Beijing in June 2011.

Jami currently resides in Washington, DC with her husband and three children.